Highlights of weekly biotech stock moves
Regulatory, clinical and other milestones
Arena Pharmaceuticals Inc. (NASDAQ:ARNA) gained $1.78 (27%) to $8.40 last week ahead of a June 27 PDUFA date for an NDA for lorcaserin to treat obesity.
BTG plc (LSE:BTG) was off 1.80p to 398p on Friday after Johnson & Johnson (NYSE:JNJ) submitted regulatory applications to FDA and EMA for Zytiga abiraterone acetate to treat chemotherapy-naive patients with metastatic castration-resistant prostate cancer (CRPC) who are asymptomatic or mildly asymptomatic after failing androgen deprivation therapy. It already is approved in the U.S. and EU in combination with prednisone or prednisolone to treat patients with metastatic CRPC who have received prior